The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
2018 · Science · 2,833 citations
https://doi.org/10.1126/science.aao3290
J
Jason J. Luke
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
806
Papers
22.6K
Citations
63
h-index
209
i10-index
Jason J. Luke is an academic researcher from VA Portland Health Care System. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research & Immunotherapy and Immune Responses. The author has an h-index of 63, co-authored 686 publications.
ORCID: 0000-0002-1182-4908Papers by this author
worksSafety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016 · Journal of Clinical Oncology · 840 citations
https://doi.org/10.1200/jco.2016.67.9761
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
2014 · Clinical Cancer Research · 772 citations
https://doi.org/10.1158/1078-0432.ccr-13-2482
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
2020 · Cancer Cell · 361 citations
https://doi.org/10.1016/j.ccell.2020.08.005
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
2022 · Nature Medicine · 144 citations
https://doi.org/10.1038/s41591-022-02015-7
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
2022 · Journal of Clinical Oncology · 96 citations
https://doi.org/10.1200/jco.22.00202
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat